GC
DFTX

Gruss & Co’s Definium Therapeutics DFTX Stock Holding History

Gruss & Co’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,939
Closed -$99.1K – 27
2025
Q1 		$99.1K Buy
+16,939
New +$121K 0.43% 25

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gruss & Co's DFTX Position: Q2 2025 in Review

Gruss & Co sold out of Definium Therapeutics (DFTX) in Q2 2025, closing a stake of 16,939 shares — an estimated $99.1K sold.

Gruss & Co first reported a position in DFTX in Q1 2025 and held it in 1 quarter. The position peaked at $99.1K in Q1 2025. 181 funds tracked by Wall St. Rank hold DFTX as of Q2 2025.

  • Gruss & Co reported no remaining Definium Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Gruss & Co sold 16,939 Definium Therapeutics shares in Q2 2025, an estimated $99.1K.
  • Gruss & Co first reported a position in Definium Therapeutics in Q1 2025 and held it in 1 quarter.
  • Gruss & Co's Definium Therapeutics position peaked at $99.1K in Q1 2025.
  • 181 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2025.

Based on Gruss & Co's 13F filing for Q2 2025, filed 5 Aug 2025.